Hazenberg Bouke P C, van Rijswijk Martin H, Lub-de Hooge Marjolijn N, Vellenga Edo, Haagsma Elizabeth B, Posthumus Marcel D, Jager Pieter L
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J Nucl Med. 2007 Jun;48(6):865-72. doi: 10.2967/jnumed.106.039313. Epub 2007 May 15.
Serum amyloid P component (SAP) binds to amyloid. (123)I-SAP scintigraphy is used to evaluate the extent and distribution of amyloid in systemic amyloidosis and has great clinical value in the detection of systemic amyloidosis. The aim of the study was to assess during scintigraphy the diagnostic performance and prognostic value of a simple parameter describing extravascular (123)I-SAP retention in systemic amyloidosis.
Two hundred megabecquerels of (123)I-labeled human SAP was injected intravenously for scintigraphy in 20 controls and in 189 consecutive patients with systemic and localized amyloidosis. Extravascular retention of (123)I-SAP was quantified from serum and urine measurements after 24 h (EVR(24)) and 48 h. Sensitivity and specificity were assessed, and retention was correlated with kidney, heart, liver, and nerve involvement and with survival.
The cutoff value representing a desired specificity of 90% of EVR(24) was 50%. The associated sensitivity of EVR(24) for detecting reactive systemic, immunocyte-derived (AL), and hereditary amyloidosis was 65%, 61%, and 22%, respectively, using a cutoff point of 50%. In AL amyloidosis, the EVR(24) increased with the number of organs involved (from a mean of 43% for 1 organ to a mean of 81% for 4 organs). The EVR(24) correlated with serum alkaline phosphatase (r = 0.63) and with creatinine clearance (r = -0.36). In AL amyloidosis, both cardiac involvement (hazard ratio, 3.9; 95% CI, 2.0-7.8) and EVR(24) (hazard ratio, 2.0; 95% CI, 1.1-3.9) were independent predictors of survival.
In AL amyloidosis, the EVR(24) is strongly associated with organ involvement and with prognosis and might serve as an indicator of the body amyloid load. Quantification of SAP retention using the EVR(24) has no additional value over (123)I-SAP scintigraphy in the detection of systemic amyloidosis.
血清淀粉样蛋白P成分(SAP)与淀粉样蛋白结合。碘(123)-SAP闪烁扫描术用于评估系统性淀粉样变性中淀粉样蛋白的范围和分布,在系统性淀粉样变性的检测中具有重要临床价值。本研究的目的是在闪烁扫描期间评估一个描述系统性淀粉样变性血管外碘(123)-SAP滞留的简单参数的诊断性能和预后价值。
对20名对照者和189例连续的系统性和局限性淀粉样变性患者静脉注射200兆贝可的碘(123)标记的人SAP进行闪烁扫描。在24小时(EVR(24))和48小时后,通过血清和尿液测量对碘(123)-SAP的血管外滞留进行定量。评估敏感性和特异性,并将滞留情况与肾脏、心脏、肝脏和神经受累情况以及生存率相关联。
代表EVR(24)期望特异性为90%的临界值为50%。使用50%的临界值时,EVR(24)检测反应性系统性、免疫细胞衍生(AL)和遗传性淀粉样变性的相关敏感性分别为65%、61%和22%。在AL淀粉样变性中,EVR(24)随着受累器官数量的增加而升高(从1个器官的平均43%增至4个器官的平均81%)。EVR(24)与血清碱性磷酸酶(r = 0.63)和肌酐清除率(r = -0.36)相关。在AL淀粉样变性中,心脏受累(风险比,3.9;95%可信区间,2.0 - 7.8)和EVR(24)(风险比,2.0;95%可信区间,1.1 - 3.9)均为生存的独立预测因素。
在AL淀粉样变性中,EVR(24)与器官受累及预后密切相关,可能作为体内淀粉样蛋白负荷的指标。在系统性淀粉样变性的检测中,使用EVR(24)对SAP滞留进行定量相对于碘(123)-SAP闪烁扫描术并无额外价值。